MedTrace Logo

Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion

NCT07185022 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 282

Last updated 2026-04-16

No results posted yet for this study

Summary

Acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) or severe stenosis poses a significant clinical challenge. Recent large randomized controlled trials, DISTAL and ESCAPE-MeVO, demonstrated no significant benefit of endovascular therapy in patients with MeVO. Although intra-arterial thrombolysis has shown promise in clinical experience, robust evidence supporting its efficacy in MeVO or severe stenosis-related AIS is still absent. To fill this gap, the RESCUE MeVO trial has been designed as a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study to evaluate the efficacy and safety of intra-arterial thrombolysis in patients with AIS caused by MeVO or severe stenosis.

Conditions

  • Stroke
  • Cerebrovascular Disorders
  • Brain Diseases
  • Nervous System Diseases
  • Vascular Diseases
  • Ischemic Stroke
  • Infarction
  • Medium Vessel Occlusion

Interventions

PROCEDURE

Intra-arterial Thrombolysis

rhTNK-tPA（Tenecteplase）dose: 0.4 - 1.2mg/min, maximum dose: 16mg. Patients who have not received IVT are recommended to initiate intra-arterial administration at a rate of 0.8 mg/min, whereas those who have received IVT are recommended to receive 0.4 mg/min. The infusion rate may be dynamically adjusted by the operator according to intra-procedural circumstances, with a maximum rate not exceeding 1.2 mg/min.

DRUG

Best Medical Treatment

Patients in this group will receive standard medical therapy in accordance with the guideline-directed management for acute ischemic stroke.

Sponsors & Collaborators

  • The Second Hospital of Anhui Medical University

    lead OTHER

Principal Investigators

  • Qi Li, professor · The Second Hospital of Anhui Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-06
Primary Completion
2030-02-01
Completion
2030-05-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07185022 on ClinicalTrials.gov